Darling Ingredients Introduces Nextida™ GC
Darling Ingredients Inc. (NYSE: DAR) has introduced Nextida™ GC, a new collagen peptide designed to reduce post-meal glucose spikes in healthy individuals. A clinical trial conducted by Darling's brand Rousselot showed that a 5-gram or 10-gram dose taken 30 minutes before a meal significantly lowered post-meal glucose spike by an average of 42%.
CEO Randall C. Stuewe stated that Darling Ingredients has discovered a way to use natural collagen for targeted health benefits through a proprietary process. Nextida GC is the first of many collagen-based solutions with targeted health benefits that the company is developing. The company continues to demonstrate how collagen can be effectively used to target common health and wellness benefits, with patents pending on their scientific work.
Darling Ingredients Inc. (NYSE: DAR) ha introdotto Nextida™ GC, un nuovo peptide di collagene progettato per ridurre i picchi di glucosio post-pasto in individui sani. Un trial clinico condotto dal marchio di Darling, Rousselot, ha mostrato che una dose di 5 grammi o 10 grammi assunta 30 minuti prima del pasto ha ridotto significativamente il picco di glucosio post-pasto di una media del 42%.
Il CEO Randall C. Stuewe ha dichiarato che Darling Ingredients ha scoperto un modo per utilizzare il collagene naturale per benefici specifici per la salute tramite un processo proprietario. Nextida GC è il primo di molti soluzioni a base di collagene con benefici per la salute mirati che l'azienda sta sviluppando. L'azienda continua a dimostrare come il collagene possa essere usato efficacemente per affrontare comuni problemi di salute e benessere, con brevetti in attesa per il loro lavoro scientifico.
Darling Ingredients Inc. (NYSE: DAR) ha presentado Nextida™ GC, un nuevo péptido de colágeno diseñado para reducir los picos de glucosa postcomida en individuos sanos. Un ensayo clínico realizado por la marca de Darling, Rousselot, mostró que una dosis de 5 gramos o 10 gramos tomada 30 minutos antes de una comida redujo significativamente el pico de glucosa postcomida en un promedio del 42%.
El CEO Randall C. Stuewe declaró que Darling Ingredients ha descubierto una forma de utilizar colágeno natural para beneficios de salud específicos a través de un proceso propietario. Nextida GC es la primera de muchas soluciones a base de colágeno con beneficios de salud dirigidos que la compañía está desarrollando. La compañía continúa demostrando cómo se puede utilizar el colágeno de manera eficaz para abordar beneficios comunes de salud y bienestar, con patentes pendientes sobre su trabajo científico.
Darling Ingredients Inc. (NYSE: DAR)는 건강한 개인의 식사 후 혈당 급증을 줄이기 위해 설계된 새로운 콜라겐 펩타이드 Nextida™ GC를 소개했습니다. Darling의 브랜드 Rousselot가 실시한 임상 시험에 따르면, 식사 30분 전에 5그램 또는 10그램의 용량을 섭취하면 식사 후 혈당 급증을 평균 42% 감소시켰습니다.
CEO 랜달 C. 스튜에는 Darling Ingredients가 독점적인 과정을 통해 자연 콜라겐을 이용하여 특정 건강 이익을 위한 방법을 발견했다고 말했습니다. Nextida GC는 회사가 개발 중인 특정 건강 이익을 가진 많은 콜라겐 기반 솔루션 중 첫 번째입니다. 이 회사는 콜라겐이 일반적인 건강 및 웰빙 이익을 타겟팅하는 데 효과적으로 사용될 수 있는 방법을 계속해서 보여주고 있으며, 과학적 작업에 대한 특허가 대기 중입니다.
Darling Ingredients Inc. (NYSE: DAR) a lancé Nextida™ GC, un nouveau peptide de collagène conçu pour réduire les pics de glucose après les repas chez les individus en bonne santé. Un essai clinique mené par la marque Rousselot de Darling a montré qu'une dose de 5 grammes ou 10 grammes prise 30 minutes avant un repas a significativement réduit le pic de glucose post-repas de 42 % en moyenne.
Le PDG Randall C. Stuewe a déclaré que Darling Ingredients a découvert une manière d'utiliser le collagène naturel pour des bénéfices ciblés pour la santé grâce à un processus propriétaire. Nextida GC est le premier d'une série de solutions à base de collagène avec des bénéfices pour la santé ciblés que l'entreprise développe. L'entreprise continue de démontrer comment le collagène peut être utilisé efficacement pour cibler des avantages courants pour la santé et le bien-être, avec des brevets en attente sur son travail scientifique.
Darling Ingredients Inc. (NYSE: DAR) hat Nextida™ GC eingeführt, ein neues Kollagenpeptid, das darauf abzielt, die postprandialen Blutzuckerspitzen bei gesunden Personen zu reduzieren. Eine klinische Studie, die von Darling's Marke Rousselot durchgeführt wurde, zeigte, dass eine Dosis von 5 Gramm oder 10 Gramm, die 30 Minuten vor einer Mahlzeit eingenommen wurde, die postprandiale Blutzuckerspitze im Durchschnitt um 42% signifikant senkte.
CEO Randall C. Stuewe erklärte, dass Darling Ingredients einen Weg gefunden hat, natürliches Kollagen für gezielte Gesundheitsvorteile durch einen proprietären Prozess zu nutzen. Nextida GC ist die erste von vielen kollagenbasierten Lösungen mit gezielten Gesundheitsvorteilen, die das Unternehmen entwickelt. Das Unternehmen demonstriert weiterhin, wie Kollagen effektiv eingesetzt werden kann, um gängige Gesundheits- und Wellnessvorteile anzusprechen, mit ausstehenden Patenten für ihre wissenschaftliche Arbeit.
- Introduction of Nextida™ GC, a new collagen peptide product
- Clinical trial showed 42% average reduction in post-meal glucose spike
- Development of proprietary process for targeted health benefits using natural collagen
- Potential for new product line of collagen-based solutions
- Patents pending on scientific work related to collagen applications
- None.
Insights
The launch of Nextida™ GC represents a significant advancement in Darling Ingredients' collagen product line. This new collagen peptide, targeting post-meal glucose spikes, could potentially address a large market concerned with blood sugar management.
Key points to consider:
- The clinical trial results showing a
42% average reduction in post-meal glucose spikes are impressive and could attract attention from both consumers and healthcare professionals. - This product launch aligns with the growing trend of functional foods and nutraceuticals, potentially opening new revenue streams for Darling Ingredients.
- The company's focus on developing collagen-based solutions with targeted health benefits suggests a strong R&D pipeline, which could lead to future product launches and market expansion.
While the immediate financial impact may be , the long-term potential for Nextida™ GC and similar products in development could significantly boost Darling Ingredients' position in the health and wellness market. Investors should monitor sales traction and any partnerships or distribution deals that may follow this launch.
Darling Ingredients' introduction of Nextida™ GC taps into several key market trends:
- The global collagen market is experiencing robust growth, with increasing demand for functional ingredients in food, beverages and supplements.
- There's a rising consumer interest in blood sugar management, not just among diabetics but also health-conscious individuals.
- The product's efficacy in reducing post-meal glucose spikes by
42% could give it a competitive edge in the crowded nutraceutical space.
However, market success will depend on factors such as pricing strategy, marketing efforts and regulatory approvals in various markets. The company's emphasis on science-backed claims and pending patents could help differentiate Nextida™ GC from competitors. Investors should watch for partnerships with food and beverage companies, as well as adoption rates among healthcare professionals, which could significantly impact the product's market penetration and revenue potential.
Next Generation Collagen Peptide that Targets Post-Meal Glucose Spike
"Darling Ingredients has unlocked the next wave of collagen-based solutions that are truly revolutionary. Produced through our proprietary process, we have discovered a way to use natural collagen for targeted health benefits," said Randall C. Stuewe, Chairman and CEO.
Nextida GC is the first of many collagen-based solutions with targeted health benefits that the company is developing.
"Our scientific work continues to demonstrate how collagen can effectively be used to target common health and wellness benefits," Stuewe said. "Built on science with patents pending, we continue to unveil the power of collagen to help us live happy, healthier lives."
About Darling Ingredients
A pioneer in circularity, Darling Ingredients Inc. (NYSE: DAR) takes material from the animal agriculture and food industries, and transforms them into valuable ingredients that nourish people, feed animals and crops, and fuel the world with renewable energy. The company operates over 260 facilities in more than 15 countries and processes about
Cautionary Statements Regarding Forward-Looking Information
This release may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals and strategies and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied by the forward-looking statements contained in this release. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.
Darling Ingredients Contacts | |
Investors: | Suann Guthrie |
Senior VP, Investor Relations, Sustainability & Communications | |
(469) 214-8202; suann.guthrie@darlingii.com | |
Media: | Jillian Fleming |
Director, Global Communications | |
(972) 541-7115; jillian.fleming@darlingii.com | |
1 First clinical trial involved 16 healthy individuals who took 1 dose of Nextida GC before a meal.
2 Reduced post-meal glucose spike by
View original content to download multimedia:https://www.prnewswire.com/news-releases/darling-ingredients-introduces-nextida-gc-302269148.html
SOURCE Darling Ingredients Inc.
FAQ
What is Nextida™ GC and how does it affect glucose levels?
How did Darling Ingredients (DAR) develop Nextida™ GC?
What are Darling Ingredients' (DAR) future plans for collagen-based products?
Who conducted the clinical trial for Nextida™ GC by Darling Ingredients (DAR)?
